| Literature DB >> 27402229 |
Heerajnarain Bulluck1, Stefania Rosmini2, Amna Abdel-Gadir2, Steven K White1, Anish N Bhuva2, Thomas A Treibel2, Marianna Fontana2, Esther Gonzalez-Lopez3, Patricia Reant4, Manish Ramlall1, Ashraf Hamarneh1, Alex Sirker5, Anna S Herrey2, Charlotte Manisty2, Derek M Yellon6, Peter Kellman7, James C Moon5, Derek J Hausenloy8.
Abstract
BACKGROUND: Whether the remote myocardium of reperfused ST-segment elevation myocardial infarction (STEMI) patients plays a part in adverse left ventricular (LV) remodeling remains unclear. We aimed to use automated extracellular volume fraction (ECV) mapping to investigate whether changes in the ECV of the remote (ECVR emote) and infarcted myocardium (ECVI nfarct) impacted LV remodeling. METHODS ANDEntities:
Keywords: ST‐segment elevation myocardial infarction; T1 mapping; T2 mapping; extracellular volume fraction; left ventricular remodeling
Mesh:
Year: 2016 PMID: 27402229 PMCID: PMC5015393 DOI: 10.1161/JAHA.116.003555
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Example of LGE images and ECV maps of an acute and follow‐up scan of a patient with an anterior STEMI. The arrows show the area of LGE with a core of MVO on the acute scan and the corresponding chronic LGE and ECV. ECV indicates extracellular volume fraction; LGE, late gadolinium enhancement; MVO, microvascular obstruction; STEMI, ST‐segment elevation myocardial infarction.
Figure 2Example of generated bull's eye plots with AHA segments from the maps and LGE images. AHA indicates American Heart Association; ECV, extracellular volume fraction; LGE, late gadolinium enhancement.
Figure 3STEMI patients screening and recruitment flow chart. CMR indicates cardiovascular magnetic resonance imaging; STEMI, ST‐segment elevation myocardial infarction.
Acute CMR Characteristics Between Patients Who Completed Paired Acute and Follow‐up Scans (n=40) and Patients Who Only Had the Acute Scan (n=8)
| Patients With Paired CMR (n=40) | Patients With Acute CMR Only (n=8) |
| |
|---|---|---|---|
| Acute LV EDV, mL | 172±38 | 135±28 | 0.01 |
| Acute indexed LV EDV, mL/m2 | 87±13 | 73±13 | 0.01 |
| Acute LV ESV, mL | 90±30 | 66±20 | 0.04 |
| Acute indexed LV ESV, mL/m2 | 45±13 | 36±11 | 0.07 |
| Acute LV EF, % | 49±8 | 52±8 | 0.32 |
| Acute LV mass, g | 111 (92–124) | 137 (86–154) | 0.28 |
| Acute MI size, % of LV | 28 (14.8–38.0) | 24.0 (23.0–25.8) | 0.52 |
| AAR, % of LV | 42.0±12.0 | 46.4±10.9 | 0.34 |
| MVO, % | 26 (65%) | 5 (63%) | 0.60 |
| Acute T2Remote, ms | 50 (48–52) | 49 (48–54) | 0.78 |
| Acute T1Remote, ms | 1026 (990–1077) | 1043 (963–1095) | 0.80 |
| Acute ECVRemote, % | 28.1 (26.2–29.7) | 27.6 (26.2–31.2) | 0.73 |
AAR indicates area‐at‐risk; CMR, cardiovascular magnetic resonance imaging; EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; LV, left ventricle; MVO, microvascular obstruction.
Denotes statistical significance at P<0.05.
Clinical Characteristics of STEMI Patients (n=40)
| Details | No. |
|---|---|
| No. of patients | 40 |
| Male (%) | 35 (88) |
| Age, y | 59±13 |
| Diabetes mellitus (%) | 8 (20) |
| Hypertension (%) | 14 (35) |
| Smoking (%) | 12 (30) |
| Dyslipidemia (%) | 14 (35) |
| Chest pain onset to PPCI time, min | 267 [122–330] |
| Infarct artery (%) | |
| LAD | 24 (60) |
| RCA | 14 (35) |
| Cx | 2 (5) |
| Pre‐PPCI TIMI flow (%) | |
| 0 | 33 (83) |
| 1 | 0 (0) |
| 2 | 3 (8) |
| 3 | 4 (10) |
| Post‐PPCI TIMI flow (%) | |
| 0 | 1 (3) |
| 1 | 0 (0) |
| 2 | 8 (20) |
| 3 | 31 (77) |
| Treatment—during PPCI (%) | |
| Aspirin | 100 (100) |
| Clopidogrel | 24 (60) |
| Ticagrelor | 16 (40) |
| Heparin | 36 (90) |
| Bivalirudin | 11 (28) |
| Glycoprotein IIbIIIa inhibitors | 11 (28) |
| Treatment—on discharge (%) | |
| Dual antiplatelet therapy | 40 (100) |
| Beta‐blockers | 40 (100) |
| ACEI/ARB | 40 (100) |
| Statin | 39 (98) |
| MRA | 10 (25) |
ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; Cx, circumflex artery; LAD, left anterior descending artery; MRA, mineralocorticoid receptor antagonist; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST‐segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
CMR Findings (n=40 STEMI Patients and n=20 Controls)
| Controls (n=20) | Acute Scan (n=40) | Follow‐up Scan (n=40) | Change Between Acute and Follow‐up |
| |
|---|---|---|---|---|---|
| LV EDV, mL | 148±34 | 172±38 | 182±49 | −9±25 |
0.02 |
| LV ESV, mL | 55±16 | 90±30 | 88±38 | 2±24 |
0.001 |
| LV EF, % | 63±5 | 49±8 | 53±10 | −5±8 |
0.001 |
| LV mass, g | 108±21 | 112±35 | 104±26 | 8±27 | NS |
| LV wall thickness in remote myocardium—diastole, mm | 7.2±0.7 | 7.1±1.3 | 6.7±1.3 | 0.4±1.3 | NS |
| LV wall thickness in remote myocardium—systole, mm | 12.0±1.3 | 12.0±1.8 | 11.2±1.8 | 0.8±2.3 | NS |
| LV wall thickening in remote myocardium, % | 66±14 | 77±40 | 75±26 | 2±43 | NS |
| LV wall motion in remote myocardium, mm | 7.7±2.5 | 9.2±2.6 | 8.9±2.6 | 0.3±2.9 |
0.04 |
| Infarct size, % of LV | NA | 27.4±14.6 | 19.5±10.5 | 7.9±7.2 | 0.0001 |
| Infarct size, g | NA | 20.2±13.6 | 14.4±9.4 | 5.8±5.9 | 0.0001 |
| AAR, % of LV | NA | 42.0±12.0 | NA | NA | |
| T2Remote, ms | 50±4 | 50±3 | 48±2 | 1±3 |
0.94 |
| T2Infarct, ms | NA | 65±5 | 57±5 | 9±7 | 0.0001 |
| T2Core, ms | NA | 51±5 | 47±3 | 4±5 | 0.001 |
| T1Remote, ms | 1000±25 | 1032±51 | 1004±39 | 29±52 |
0.001 |
| T1Infarct, ms | NA | 1245±75 | 1141±53 | 104±88 | 0.0001 |
| T1Core, ms | NA | 1025±89 | 1029±52 | −5±79 | 0.74 |
| ECVRemote, % | |||||
| Whole cohort (n=40) | 26.4±2.1 | 27.9±2.1 | 27.0±2.1 | 0.9±1.9 |
0.01 |
| With adverse LV remodeling (n=8) | NA | 29.5±1.4 | 28.6±1.5 | 0.9±2.2 | 0.27 |
| Without adverse LV remodeling (n=32) | NA | 27.4±2.0 | 26.6±2.1 | 0.9±1.9 | 0.02 |
| ECVInfarct, % | NA | 69.2±9.6 | 70.4±19.9 | −1.2±18.3 | 0.71 |
AAR indicates area‐at‐risk; CMR, cardiovascular magnetic resonance imaging; ECV, extracellular volume fraction; EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; LV, left ventricle; MVO, microvascular obstruction; NA, not applicable; NS, not statistically significant; STEMI, ST‐segment elevation myocardial infarction.
Control vs acute scan.
Control vs follow‐up scan.
Intraobserver and Interobserver Variability for ECV Using 2 Different Techniques (Mean Segmental Values and Manual ROI; n=10)
| Intraclass Correlation Coefficient (95% CI) | Bias±Limits of Agreement (%) | |
|---|---|---|
| Intraobserver variability (n=10) | ||
| ECVRemote | ||
| Mean segmental values | 0.994 (0.976–0.998) | 0.11±1.22 |
| Manual ROI | 0.981 (0.922–0.995) | 0.42±1.59 |
| ECVInfarct | ||
| Mean segmental values | 0.992 (0.967–0.998) | 0.53±2.44 |
| Manual ROI | 0.972 (0.886–0.993) | 0.13±5.02 |
| Interobserver variability (n=10) | ||
| ECVRemote | ||
| Mean segmental values | 0.996 (0.984–0.999) | 0.10±0.99 |
| Manual ROI | 0.989 (0.958–0.997) | 0.18±1.40 |
| ECVInfarct | ||
| Mean segmental values | 0.991 (0.949–0.998) | 0.81±2.21 |
| Manual ROI | 0.963 (0.850–0.991) | 0.10±5.96 |
ECV indicates extracellular volume fraction; ROI, region of interest.
Figure 4T2 and ECV of the remote myocardium in STEMI patients with (n=8) and without LV remodeling (n=32). ECV indicates extracellular volume fraction; LV, left ventricular; STEMI, ST‐segment elevation myocardial infarction. *Denotes statistical significance at P<0.05.
Univariable and Multivariable Associates of LV Remodeling (n=40)
| Univariable Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|
| Regression Slope |
|
| Regression Slope |
| |
| MSI | −29 | 0.25 | 0.001 | −25 | 0.008 |
| ECV remote | 3.5 | 0.24 | 0.001 | 2.6 | 0.03 |
| MVO, g | 2.7 | 0.26 | 0.001 | NS | |
| T1 remote | 0.13 | 0.20 | 0.03 | NS | |
| T1Core | −0.06 | 0.14 | 0.001 | NS | |
ECV indicates extracellular volume fraction; LV, left ventricle; MSI, myocardial salvage index; MVO, microvascular obstruction; NS, not statistically significant.